Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level

BMC Neuroscience

Volumn 10, Issue , 2009, Pages

  Barbier, Elisabeth ^a   Wang, Jia B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CORTICOSTERONE; PROTEIN HINT I; PROTEIN KINASE C INTERACTING PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; HINT1 PROTEIN, MOUSE; NERVE PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; FORCED SWIMMING TEST; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEARNING; MAZE TEST; MEMORY; MOOD; MOUSE; NONHUMAN; PHENOTYPE; TRANQUILIZING ACTIVITY; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; ASSOCIATION; AVOIDANCE BEHAVIOR; BLOOD; DEPRESSION; DRUG EFFECT; EXPLORATORY BEHAVIOR; GENETICS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMOBILIZATION; MALE; MOUSE MUTANT; PHYSIOLOGY; RECALL; REGRESSION ANALYSIS; SWIMMING; TIME; TONIC IMMOBILITY;

ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CORTICOSTERONE; CUES; DEPRESSION; EXPLORATORY BEHAVIOR; HINDLIMB SUSPENSION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMOBILITY RESPONSE, TONIC; MALE; MAZE LEARNING; MENTAL RECALL; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; PITUITARY-ADRENAL SYSTEM; REGRESSION ANALYSIS; SPATIAL BEHAVIOR; SWIMMING; TIME FACTORS; VALPROIC ACID;

EID: 71049143223     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-10-132     Document Type: Article

References (74)

1. Davidson RJ, Lewis DA, Alloy LB, Amaral DG, Bush G, Cohen JD, Drevets WC, Farah MJ, Kagan J, McClelland JL, Nolen-Hoeksema S, Peterson BS. Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry 2002, 52:478-502. 10.1016/S0006-3223(02)01458-0, 12361665.
2. Crawley JN, Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 1997, 31:197-211. 10.1006/hbeh.1997.1382, 9213134.
3. Porsolt RD, Le PM, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732. 10.1038/266730a0, 559941.
4. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370. 10.1007/BF00428203, 3923523.
5. Porsolt RD. Animal models of depression: utility for transgenic research. Rev Neurosci 2000, 11:53-58.
6. Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 2004, 9:326-357. 10.1038/sj.mp.4001457, 14743184.
7. Einat H. Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet 2007, 37:244-255. 10.1007/s10519-006-9093-4, 16865528.
8. Gould TD, Einat H. Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev 2007, 31:825-831. 2150564, 17628675, 10.1016/j.neubiorev.2007.05.007.
9. Einat H. Modelling facets of mania--new directions related to the notion of endophenotypes. J Psychopharmacol 2006, 20:714-722. 10.1177/0269881106060241, 16401660.
10. Crawley JN. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 1999, 835:18-26. 10.1016/S0006-8993(98)01258-X, 10448192.
11. Onaivi ES, Martin BR. Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety. Prog Neuropsychopharmacol Biol Psychiatry 1989, 13:963-976. 10.1016/0278-5846(89)90047-X, 2573111.
12. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005, 4:775-790. 10.1038/nrd1825, 16138108.
13. Choleris E, Thomas AW, Kavaliers M, Prato FS. A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. Neurosci Biobehav Rev 2001, 25:235-260. 10.1016/S0149-7634(01)00011-2, 11378179.
14. Johnson SL. Mania and dysregulation in goal pursuit: a review. Clin Psychol Rev 2005, 25:241-262. 10.1016/j.cpr.2004.11.002, 15642648.
15. Keck PE, McElroy SL. Divalproex in the treatment of bipolar disorder. Psychopharmacol Bull 2003, 37(Suppl 2):67-73.
16. Cao BJ, Peng NA. Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents. Eur J Pharmacol 1993, 237:177-181. 10.1016/0014-2999(93)90266-K, 8103460.
17. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002, 7:254-275. 10.1038/sj.mp.4001032, 11920153.
18. Whalley LJ, Christie JE, Blackwood DH, Bennie J, Dick H, Blackburn IM, Fink G. Disturbed endocrine function in the psychoses. I: Disordered homeostasis or disease process?. Br J Psychiatry 1989, 155:455-461. 10.1192/bjp.155.4.455, 2611570.
19. Swann AC, Stokes PE, Casper R, Secunda SK, Bowden CL, Berman N, Katz MM, Robins E. Hypothalamic-pituitary-adrenocortical function in mixed and pure mania. Acta Psychiatr Scand 1992, 85:270-274. 10.1111/j.1600-0447.1992.tb01468.x, 1595360.
20. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005, 28:469-480. 10.1016/j.psc.2005.01.005, 15826743.
21. Yamano M, Ogura H, Okuyama S, Ohki-Hamazaki H. Modulation of 5-HT system in mice with a targeted disruption of neuromedin B receptor. J Neurosci Res 2002, 68:59-64. 10.1002/jnr.10194, 11933049.
22. El Yacoubi M, Bouali S, Popa D, Naudon L, Leroux-Nicollet I, Hamon M, Costentin J, Adrien J, Vaugeois JM. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci USA 2003, 100:6227-6232. 156354, 12732720, 10.1073/pnas.1034823100.
23. Chotiwat C, Harris RB. Increased anxiety-like behavior during the post-stress period in mice exposed to repeated restraint stress. Horm Behav 2006, 50:489-495. 10.1016/j.yhbeh.2006.06.007, 16870191.
24. Touma C, Bunck M, Glasl L, Nussbaumer M, Palme R, Stein H, Wolferstatter M, Zeh R, Zimbelmann M, Holsboer F, Landgraf R. Mice selected for high versus low stress reactivity: a new animal model for affective disorders. Psychoneuroendocrinology 2008, 33:839-862. 10.1016/j.psyneuen.2008.03.013, 18502051.
25. Liu GX, Cai GQ, Cai YQ, Sheng ZJ, Jiang J, Mei Z, Wang ZG, Guo L, Fei J. Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1. Neuropsychopharmacology 2007, 32:1531-1539. 10.1038/sj.npp.1301281, 17164814.
26. Murray F, Smith DW, Hutson PH. Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. Eur J Pharmacol 2008, 583:115-127. 10.1016/j.ejphar.2008.01.014, 18289522.
27. Klein MG, Yao Y, Slosberg ED, Lima CD, Doki Y, Weinstein IB. Characterization of PKCI and comparative studies with FHIT, related members of the HIT protein family. Exp Cell Res 1998, 244:26-32. 10.1006/excr.1998.4153, 9770345.
28. Lima CD, Klein MG, Weinstein IB, Hendrickson WA. Three-dimensional structure of human protein kinase C interacting protein 1, a member of the HIT family of proteins. Proc Natl Acad Sci USA 1996, 93:5357-5362. 39250, 8643579, 10.1073/pnas.93.11.5357.
29. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, Donovan DM, Webster M, Freed WJ, Becker KG. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 2001, 55:641-650. 10.1016/S0361-9230(01)00522-6, 11576761.
30. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, Freed WJ. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res 2002, 58:11-20. 10.1016/S0920-9964(01)00377-2, 12363385.
31. Vawter MP, Shannon WC, Ferran E, Matsumoto M, Overman K, Hyde TM, Weinberger DR, Bunney WE, Kleinman JE. Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem Res 2004, 29:1245-1255. 10.1023/B:NERE.0000023611.99452.47, 15176481.
32. Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ, Barci BM, Torrey EF. Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci 2007, 31:221-243.
33. Barbier E, Zapata A, Oh E, Liu Q, Zhu F, Undie A, Shippenberg T, Wang JB. Supersensitivity to amphetamine in protein kinase-C interacting protein/HINT1 knockout mice. Neuropsychopharmacology 2007, 32:1774-1782. 10.1038/sj.npp.1301301, 17203012.
34. Liu Q, Puche AC, Wang JB. Distribution and expression of protein kinase C interactive protein (PKCI/HINT1) in mouse central nervous system (CNS). Neurochem Res 2008, 33:1263-1276. 10.1007/s11064-007-9578-4, 18270824.
35. Baumann B, Bogerts B. The pathomorphology of schizophrenia and mood disorders: similarities and differences. Schizophr Res 1999, 39:141-148. 10.1016/S0920-9964(99)00113-9, 10507525.
36. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25:1-27. 10.1016/S0893-133X(01)00225-1, 11377916.
37. Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002, 55:1-10. 10.1016/S0920-9964(01)00188-8, 11955958.
38. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006, 1:848-858. 10.1038/nprot.2006.116, 17406317.
39. Save E, Poucet B. Involvement of the hippocampus and associative parietal cortex in the use of proximal and distal landmarks for navigation. Behav Brain Res 2000, 109:195-206. 10.1016/S0166-4328(99)00173-4, 10762689.
40. Gallagher M, Burwell R, Burchinal M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 1993, 107:618-626. 10.1037/0735-7044.107.4.618, 8397866.
41. Wolfer DP, Stagljar-Bozicevic M, Errington ML, Lipp HP. Spatial Memory and Learning in Transgenic Mice: Fact or Artifact?. News Physiol Sci 1998, 13:118-123.
42. Wilcoxon JS, Nadolski GJ, Samarut J, Chassande O, Redei EE. Behavioral inhibition and impaired spatial learning and memory in hypothyroid mice lacking thyroid hormone receptor alpha. Behav Brain Res 2007, 177:109-116. 1819397, 17129617, 10.1016/j.bbr.2006.10.030.
43. Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P, Porsolt RD. The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1987, 11:659-671. 10.1016/0278-5846(87)90002-9, 2894041.
44. Rodgers RJ, Boullier E, Chatzimichalaki P, Cooper GD, Shorten A. Contrasting phenotypes of C57BL/6JOlaHsd, 129S2/SvHsd and 129/SvEv mice in two exploration-based tests of anxiety-related behaviour. Physiol Behav 2002, 77:301-310. 10.1016/S0031-9384(02)00856-9, 12419406.
45. West AP. Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry 1990, 14:863-877. 10.1016/0278-5846(90)90073-P, 2277851.
46. Flaisher-Grinberg S, Einat H. A possible utilization of the mice forced swim test for modeling manic-like increase in vigor and goal-directed behavior. J Pharmacol Toxicol Methods 2009, 59:141-145. 10.1016/j.vascn.2009.03.003, 19341808.
47. Plotsky PM, Owens MJ, Nemeroff CB. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am 1998, 21:293-307. 10.1016/S0193-953X(05)70006-X, 9670227.
48. Chu Y, Mouat MF, Harris RB, Coffield JA, Grider A. Water maze performance and changes in serum corticosterone levels in zinc-deprived and pair-fed rats. Physiol Behav 2003, 78:569-578. 10.1016/S0031-9384(03)00041-6, 12782210.
49. Cameron OG, Nesse RM. Systemic hormonal and physiological abnormalities in anxiety disorders. Psychoneuroendocrinology 1988, 13:287-307. 10.1016/0306-4530(88)90054-6, 2906440.
50. Gallagher P, Watson S, Smith MS, Young AH, Ferrier IN. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res 2007, 90:258-265. 10.1016/j.schres.2006.11.020, 17222537.
51. Linkowski P, Mendlewicz J, Leclercq R, Brasseur M, Hubain P, Golstein J, Copinschi G, Van CE. The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. J Clin Endocrinol Metab 1985, 61:429-438. 10.1210/jcem-61-3-429, 2991318.
52. Malisch JL, Saltzman W, Gomes FR, Rezende EL, Jeske DR, Garland T. Baseline and stress-induced plasma corticosterone concentrations of mice selectively bred for high voluntary wheel running. Physiol Biochem Zool 2007, 80:146-156. 10.1086/508828, 17160887.
53. Benazzi F. Bipolar II disorder: epidemiology, diagnosis and management. CNS Drugs 2007, 21:727-740. 10.2165/00023210-200721090-00003, 17696573.
54. Colorado RA, Shumake J, Conejo NM, Gonzalez-Pardo H, Gonzalez-Lima F. Effects of maternal separation, early handling, and standard facility rearing on orienting and impulsive behavior of adolescent rats. Behav Processes 2006, 71:51-58. 10.1016/j.beproc.2005.09.007, 16242858.
55. Steiner J. A questionnaire study of risk-taking in psychiatric patients. Br J Med Psychol 1972, 45:365-374.
56. Swann AC, Steinberg JL, Lijffijt M, Moeller FG. Impulsivity: differential relationship to depression and mania in bipolar disorder. J Affect Disord 2008, 106:241-248. 2683682, 17822778, 10.1016/j.jad.2007.07.011.
57. Vieta E, Martinez-De-Osaba MJ, Colom F, Martinez-Aran A, Benabarre A, Gasto C. Enhanced corticotropin response to corticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients. Psychol Med 1999, 29:971-978. 10.1017/S0033291799008727, 10473324.
58. Harrison-Read PE. Models of mania and antimanic drug actions: progressing the endophenotype approach. J Psychopharmacol 2009, 23:334-337. 10.1177/0269881108089840, 18583431.
59. Brenner C, Bieganowski P, Pace HC, Huebner K. The histidine triad superfamily of nucleotide-binding proteins. J Cell Physiol 1999, 181:179-187. 2556047, 10497298, 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8.
60. Catapano LA, Manji HK. Kinases as drug targets in the treatment of bipolar disorder. Drug Discov Today 2008, 13:295-302. 10.1016/j.drudis.2008.02.007, 18405841.
61. Guang W, Wang H, Su T, Weinstein IB, Wang JB. Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphine-induced analgesia. Mol Pharmacol 2004, 66:1285-1292. 10.1124/mol.66.5., 15496510.
62. Rodriguez-Munoz M, de L, Sanchez-Blazquez P, Wang JB, Garzon J. NMDAR-nNOS generated zinc recruits PKCgamma to the HINT1-RGS17 complex bound to the C terminus of Mu-opioid receptors. Cell Signal 2008, 20:1855-1864. 10.1016/j.cellsig.2008.06.015, 18652891.
63. Davis GC, Buchsbaum MS, Bunney WE. Analgesia to painful stimuli in affective illness. Am J Psychiatry 1979, 136:1148-1151.
64. Schaffer CB, Nordahl TE, Schaffer LC, Howe J. Mood-elevating effects of opioid analgesics in patients with bipolar disorder. J Neuropsychiatry Clin Neurosci 2007, 19:449-452.
65. Judd LL, Parker DC, Janowsky DS, Segal DS, Risch SC, Huey LY. The effect of methadone on the behavioral and neuroendocrine responses of manic patients. Psychiatry Res 1982, 7:163-170. 10.1016/0165-1781(92)90089-L, 6959168.
66. Hoehe M, Duka T, Doenicke A. Human studies on the mu opiate receptor agonist fentanyl: neuroendocrine and behavioral responses. Psychoneuroendocrinology 1988, 13:397-408. 10.1016/0306-4530(88)90046-7, 2849775.
67. Leslie RD, Prescott RW, Kendall-Taylor P, Cook D, Weightman D, Ratcliffe J, Ingram MC. Opiate receptor blockade and diurnal pituitary and adrenal hormone levels. Horm Metab Res 1985, 17:86-89. 10.1055/s-2007-1013458, 2985486.
68. Su T, Suzui M, Wang L, Lin CS, Xing WQ, Weinstein IB. Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci USA 2003, 100:7824-7829. 164672, 12810953, 10.1073/pnas.1332160100.
69. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
70. Taltavull JF, Chefer VI, Shippenberg TS, Kiyatkin EA. Severe brain hypothermia as a factor underlying behavioral immobility during cold-water forced swim. Brain Res 2003, 975:244-247. 10.1016/S0006-8993(03)02695-7, 12763614.
71. McLaughlin JP, Marton-Popovici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 2003, 23:5674-5683. 2104777, 12843270.
72. Crowley JJ, Jones MD, O'Leary OF, Lucki I. Automated tests for measuring the effects of antidepressants in mice. Pharmacol Biochem Behav 2004, 78:269-274. 10.1016/j.pbb.2004.03.014, 15219767.
73. Juszczak GR, Sliwa AT, Wolak P, Tymosiak-Zielinska A, Lisowski P, Swiergiel AH. The usage of video analysis system for detection of immobility in the tail suspension test in mice. Pharmacol Biochem Behav 2006, 85:332-338. 10.1016/j.pbb.2006.08.016, 17049370.
74. Takao K, Miyakawa T. Light/dark transition test for mice. J Vis Exp 2006, 13(1):104.